(Boursier.com) — In the first half of 2022, DMS – Diagnostic Medical Systems achieved a turnover of 18.6 million euros, a slight increase of +1% compared to the 1st half of 2021. As a reminder, DMS Group carried out the sale of the DMS Wellness division at the beginning of 2022 (0.1 ME in the 1st half of 2021).
The 2022 half-year EBITDA of the DMS Imaging division amounted to 1.9 ME, representing an EBITDA margin of 10.3%. The proforma EBITDA margin for the first half of 2021 was 9.7%.
Net income, group share was -€5.1m in the first half of 2022.
At the end of the first half of 2022, available cash is €4.1 million. Financial debt stood at 11.6 ME at June 30, leading to net financial debt of 7.5 ME, i.e. a ‘net gearing’ of 35% compared to 6.2 ME at the end of 2021 (‘net gearing’ of 30% ). As of June 30, 2022, DMS Group’s equity amounted to €21.5 million (€20.4 million as of December 31, 2021).
DMS Group confirms its plan to issue and allocate free stock warrants (BSA) to its shareholders.
Outlook
Following the evolution of the group’s governance in July 2022, the new Chairman and Chief Executive Officer of DMS Group has initiated a strategic review of all of the Group’s activities, with the aim of continuing the group’s development, capitalizing on the skills of the teams in place, and to reposition the shareholders at the center of the group’s objectives by injecting real stock market momentum.
The result of this reflection will be shared with shareholders and employees during the month of October as part of a communication aimed at presenting DMS Group’s strategic plan. This strategic plan will focus on strengthening DMS Imaging’s position as a major European player in medical imaging. On the other hand, strategic discussions are continuing on the future of the DMS Biotech division (stake of around 40% in Hybrigenics and its subsidiaries Stemcis, Adip’Sculpt, Inoviem Scientific and B Celle Design). .